New Products: Once-a-month Actonel option approved

June 1, 2008

Once monthly dose of Actonel has been approved to treating and preventing postmenopausal osteoporosis.

The Agency okayed the new dosage on the basis of a study of 642 women that compared 150 mg of Actonel monthly to 5 mg daily of the tablet. The study showed similar increases for both groups in lumbar spine bone mineral density and at other sites from baseline at 1 year. Produced by Procter and Gamble Pharmaceuticals, the drug is marketed by Sanofi-Aventis U.S. For more information on Actonel, visit the Web site at http://www.actonel.com/.